Life Sciences Archive » January, 2017

Life Sciences - January, 2017

388 articles

• Gorsuch Likely To Restore Scalia-Era High Court Balance
• Gorsuch's Credentials Could Prove Troubling To Opposition
• Calif. Appeals Court Rebuffs Arbitration In Drug Co. Battle
• Bio-Rad GC Fired For Screw-Up And Temper, CFO Testifies
• 3 Gorsuch Opinions You Need To Read Right Now
• Teva Vows Appeal After 4 Copaxone Patents Invalidated
• Drug Buyer Hits Mylan, Sandoz, Taro With Price-Fixing Suit
• Trump Nominates Judge Gorsuch For High Court Seat
• Cancer Drug Co. Founder Accuses Brace Of Takeover Plot
• Da Vinci Robot Maker Escapes Suit Over Metal Debris
• FDA Warning Wire: A Winter Enforcement Storm
• Jurors To Hear Of Depakote Delay Link Despite FDA Block
• Biotech Twist Wants 'Opportunistic' Trade Secrets Suit Tossed
• UPS Can't Shake Frozen Embryo Mistreatment Case
• FDA's Streamlined Requirements For Combination Products
• Celgene Says 9th Circ. Ruling Means $40B FCA Suit Must Go
• Actavis, Lannett Hit With Antitrust Suit Over Gallstone Drug
• Indivior Must Face Suboxone Product-Hop Suit, States Say
• 10 False Claims Act Highlights Of 2016
• Some Early Trends In Post-Grant Review
• Prosecution Of Corporate Execs: The Latest Developments
• 2 Recent Decisions Provide Stock Promotion Guidelines
• Dems Boycott Vote On Trump's HHS, Treasury Noms
• FDA, Industry Face Hurdles With Trump Regulatory Overhaul
• First J&J Talc Cancer Trial In Calif. Set For July
• Mylan Facing Antitrust Probe Over EpiPen's Market Power
• Health Reg Rollback Will Hinge On Trump Order's Vagueness
• IP, Pharma Groups Call For Patent Eligibility Law Overhaul
• Small Pharmacies Seek Redo In Medco Antitrust Row
• In Loss For Merck, Amneal Gets OK For Generic Nasal Spray
• Diabetes Patients Fire Off First Suit Over Insulin Drug Hike
• Biotech Hit With Securities Class Action Over Sham Merger
• ARIAD Investor Slams $5.2B Takeda Deal For Unfair Process
• CORRECTED: Jury Awards Evonik $1.5M In Chem Bond IP Suit
• Nominee For HHS Sec Bought Discounted Biotech Stock
• 'Remarkable' E-Cig Liquid Law Partly Put Out By 7th Circ.
• Chicago Fights Latest Effort To Kill Opioid Addiction Suit
• Sperm Mixup Suit Put On Hold Amid State Court Case
• Love And Law In The Age Of Trump
• FTC Deceived Court On Pay-For-Delay Suit, Watson Says
• Sterne Kessler Adds 2 Kellogg Huber IP Pros As Directors
• An Update On Merger Filings In China
• Walgreens Boots Cuts Rite Aid Offer, Delays Closing
• FDA Memo Does Not Simplify 1st Amendment Considerations
• Trump Signs 'One In, Two Out' Order On Rulemaking
• The State Of The Litigation Finance Industry In 2017
• 9th Circ. Backs Millennium In $8.7M False Ad Coverage Suit
• Shire Prevails In Patent Trial Over Mylan's Generic Lialda
• Calif. Appeals Court Says Bone Doc Not Expert In Nexium Suit
• $61M Ends Sanofi Vaccine Antitrust Dispute
• Illumina Urges Fed. Circ. To Broaden Reach Of AIA Estoppel
• Hyland Homeopathic Teething Tablets Are Toxic, FDA Says
• Merck Pill Production Move Didn't Violate CBA, Judge Says
• Thompson & Knight Adds Litigation Partner From Reed Smith
• Taxation With Representation: Cravath, Vinson, Wachtell
• Merger Rules Shouldn't Stifle Drug Development: Vestager
• Patents Under The Trump Administration
• Health Hires: Lewis Brisbois, DLA Piper, Proskauer, Epstein
• 6 Firms To Steer IPOs Totaling $2.7B Led By Giant REIT
• 11th Circ. Ruling May Affect Criminal Securities Fraud Cases
• FDA Breaks Medical Product Communications Silence
• 'Complex' Acid-Reflux Drug Litigation Gives JPML Heartburn
• Cornerstone Investor Attys Get $4.9M In Merger Settlement
• Cynosure Agrees To Pay $16M To End Unwanted Fax TCPA Suit
• No Delay For Approaching Talc Trials, Mo. High Court Rules
• Ex-Accutane User's Time Limit Win May Draw Drug Suits To NJ
• Shkreli, Ex-Katten Atty Gear Up For Severance Fights
• Mylan, Sandoz, Taro Hiked Drug Price 1,000%, Union Says
• 5th Circ. Won't Consolidate Hip MDL Bellwether Appeals
• NY, La. Eyed For MDL Consolidation Of Blood-Thinner Suits
• Janssen Looks To Bar Sales Of Biosimilar In Remicade Suit
• 2 Life Sciences Cos. Price IPOs Totaling $172M
• Pump-Dump Fraudsters Pay SEC $9M, Firm Still Faces Suit
• Sorrento Directors Say Investor Suit Inadequately Pled
• Zimmer Gets Win In 3rd Knee Implant Bellwether
• Del. Justices Uphold Toss Of Salix-Valeant Merger Appeal
• Fed. Circ. Affirms Mylan Infringed Overdose Drug Patent
• Monsanto Fights To End Calif. Cities' PCBs Nuisance Row
• 4th Circ. Backs $3M Pelvic Mesh Verdict
• Cipro Buyers, Barr Reach $225M Deal In Pay-For-Delay Suit
• Medtronic Gets $20.3M Infringement Verdict Cut By $2.6M
• GSK Says No Basis For Fraud Claims In Zofran MDL
• Feds Tell High Court To Pass On Flanax Trademark Case
• PTAB Expertise Key Factor To Landing AIA Work, GCs Say
• Temasek Invests $800M In Alphabet's Verily Life Sciences
• 6 Ways To Get More From A Limited Budget For Trial Graphics
• Lannett, Mylan Fixed Thyroid Drug Price, Suit Says
• 4 PTAB Lessons On Scope Of On-Sale Prior Art
• J&J Grabs Swiss Rare Drug Co. Actelion In $30B Cash Deal
• EU Antitrust Watchdog Unsure About Merger Alert Reforms
• Dialysis Cos. Win Freeze Of HHS Premium Assistance Rule
• Bio-Rad GC's Corruption Report Baseless, Atty Testifies
• Deals Rumor Mill: Siemens, SK Capital Partners, Kate Spade
• Doctors Urge Fed. Circ. To Keep Cholesterol Drug On Market
• Del. Justices Seek Details In $13B Salix Merger Appeal
• Top Health Cos. Press Trump On Value-Based Care
• Hooper Lundy Adds DOJ Health Fraud Deputy In Boston
• Judge Excluded Zoloft MDL Expert Too Soon, 3rd Circ. Told
• Perrigo Seeks New Trial After $10M Patent Verdict
• Pfizer Returns Fire In Advil-Tylenol Advertising Suit
• At PTAB, Mylan Blasts AstraZeneca Over $3.5B Diabetes Meds
• EU Conditionally Approves Abbott's $5.8B Purchase Of Alere
• Carefully Tailored ERISA Claims After Amgen V. Harris
• Bio-Rad Ex-GC Asks For $8M On Contentious Trial Day
• FDA Warning Wire: Zimmer Rapped In Inspection, Again
• Pharma Refund Co. Can't Nix Evidence Of Money Laundering
• Apotex Slams Merck's Nasonex Generic Suit As Redundant
• Glaxo Looks To Bar FDA, Plea Evidence From Paxil Trial
• Valeant Says Zydus' Cardizem Generic Infringes Patent
• NJ Justices Apply That State's Time Limit To $25M Drug Suit
• A Return To Republican Antitrust Policies For Pharma
• Taxing Marijuana: A Hazy Issue For Municipal Bankruptcy
• Purdue Sued By Wash. City Over Costs Of Opioid Crisis
• Judge Allows Ariosa Invalidity Arguments From AIA Petition
• Endo Settles Pay-For-Delay Suit As FTC Renews Watson Case
• Mallinckrodt Hit With Securities Suit After $100M FTC Deal
• Bio-Rad CEO Tells Jury Ex-GC 'Came Unglued' After DOJ Fee
• Medtronic, IRS Agree On $14M Tax Bill In Transfer Pricing Row
• IRS Wants Mylan To Give Up Docs Over $400M IP Deal
• GSK Seeks Win In Denture Cream Health Effects MDL
• KaloBios Investors Take $1.5M Deal But Still Target Shkreli
• 10 Antitrust Trends And Developments To Watch This Year
• WTO Loosens Drug Patent Rules For Poorer Nations
• Hospital Wants To Triple $10M Jury Verdict Over Pepcid Patent
• Kaneka Health Supplement Patent Suit Revived By Fed. Circ.
• Deals Rumor Mill: Blackstone, Jose Cuervo, Cynosure
• Former DC Prosecutor Returns To DLA Piper
• Zimmer Wants Claims Limited In Knee Implant Trial
• Consumers Fight Alere Dismissal Bid In Blood Test Suit
• Pfizer Hits Back At Texas In Rebate Info Disclosures Suit
• Bayer Suit Over False Mirena Price Listing Survives
• Calif. Judge Trims Supplement Buyer's False Ad Suit
• Everything To Know About EPA's Final Nanoscale Rule
• Merck Pays Bristol-Myers $625M In Cancer Treatment IP Row
• Obama's FDA Leaves Mark With Last-Minute Policy Blitz
• 8 Firms To Steer IPOs Totaling $1.9B As 2017 Gets Cranking
• Head Of Meningitis-Linked Pharmacy Called Regulators Inept
• Anthem Agrees To Lift Extra Step In Opioid Rehab Coverage
• Agile Lied About Birth Control Patch Study, Investor Says
• Taxation With Representation: Cravath, Weil, Jones Day, Davis
• Sanction Bid in Dismissed IP Case Still Valid, Sloan Says
• Herbalife In SEC Hot Seat Over China Anti-Corruption Stance
• Bayer MDL Firm Fights 'Frivolous' Sanctions In Fee Dispute
• How Litigation Funding Is Bringing Champerty Back To Life
• Lessons From The Largest Patent Damages Award In History
• Bio-Rad CEO Tells Jury He Backdated Fired Exec's Review
• DNA Testing Customer Says Privacy Row Ideal For Class Cert.
• Alleged Ringleader Pleads Guilty In $175M Health Fraud
• Fla. AG Files Water Chemical Antitrust Suit In NJ
• The Lawyer Who Will Shape Trump's Presidency
• Most Influential Judges On Trump's Supreme Court Short List
• Rolling Back Regulation In The Age Of Trump
• In The Polarized Era Of Trump, BigLaw Searches For Balance
• Monsanto Can't Keep Ex-Atty Out Of Syngenta MDL
• AbbVie Fires Back At Investors' Suit Over Failed Merger
• Walgreens To Pay $50M To Settle Feds' Kickback Claims
• Ethicon Trims Failure To Warn Claims In Mesh MDL
• BioScrip Investors Try To Save Suit After Targeting New Board
• PTAB Invalidates RainDance Diagnostic Testing Patent
• Costco To Pay $11.75M Over Lax Pharmacy Oversight
• Judge Axes Roche TB Test Patent As Natural Phenomena
• Small Pharmacies Lose Class Cert. In Caremark Antitrust Row
• High Court To Hear Dispute Over Plavix Users' Calif. Ties
• Attracting And Retaining The Millennial Lawyer
• Devos Wants Evidence Barred In Money Laundering Case
• Hip Implant Plaintiff Shows Early Bird May Not Get The Worm
• Colgate Seeks To Brush Away Toothpaste False-Ad Suit
• Health Care Enforcement Review And 2017 Outlook: Part 4
• Niro Attys Again Face Sanctions In Sloan-Kettering IP Row
• Fraud Conviction Stands, But Atty Wins $13M Penalty Review
• Bio-Rad's Ex-GC Testifies CEO Resisted FCPA Investigation
• Widow Tells Jury Of Husband's Death From Tainted Steroids
• 5 Key Exchanges At HHS Nominee's Grilling
• $5M Deal On J&J Bedtime Baby Products OK'd
• Merck Says K-Dur Buyers Can't Save Pay-For-Delay Suit
• FDA Allows More Input On Off-Label Drug Promotion Limits
• Med Device Co. Pays $14M Over Accounting, FCPA Violations
• Private Education Giant, Biotech Launch IPOs Totaling $687M
• Asset Swap Transactions In The Antitrust Crosshairs
• New Claim Of Death Emerges In Xarelto MDL
• $21M Interest Added To CardiAQ Trade Secrets Win
• Mallinckrodt Inks $100M Antitrust Deal With FTC, States
• Pentax Medical Devices Carry Infection Risk, FDA Says
• It's Time To Change The Law Firm Business Model
• Eli Lilly Pays $960M For Migraine Treatment Developer
• Health Care Enforcement Review And 2017 Outlook: Part 3
• 2 Ways Courts Approach Willful Infringement After Halo
• FDA Adverse Event Data Release May Mean More Lawsuits
• Bio-Rad Fired GC For FCPA Leak, Jury Told At Trial's Start
• McKesson Gets $150M DOJ Fine For Ignoring Sketchy Orders
• Stem Cell Group Denies Selling Fraudulent Treatments
• 3 Takeaways As FDA Dishes On Interchangeable Biosimilars
• After Historic Vote, Fla. Drafts New Medical Pot Rules
• Stryker Accused Of Firing Specialist For Refusing Surgeries
• Drug Cos. Aim To Force Market Discovery In Loestrin MDL
• Allergan Pays $15M For Failing To Disclose Merger Talks
• Biogen To Pay $1.25B For Forward Pharma's MS Drug IP
• 7 Companies Launch IPOs Totaling $1.7B As 2017 Heats Up
• FDA's Foreign Offices Are Short-Staffed, Report Says
• Law360's Pay-For-Delay Cheat Sheet For 2017
• Jury Told Zimmer Skimped On Warnings For Obese Patients
• Justices Decline J&J Patent Appeal Over Expert Misconduct
• Key Trade Secret Developments Of 2016: Part 2
• Defibrillator Decision Does Not Shock The Conscience
• Amended Rule 37(e): 1 Year Later
• Health Care Enforcement Review And 2017 Outlook: Part 2
• Evidence Substantiation Burden May Soon Shift To FTC
• Dechert's New Hong Kong Team Seals 5 Deals In First 2 Weeks
• Bayer Gets Freebie As Atty Neglect Sinks Yasmin Suit
• FDA Issues Guidance On How It OKs Device Tests In Humans
• Spouse Of FTC Witness In Diet Pill Suit Avoids Sanctions
• Pharmacy That Sold Deadly Drugs Touted Safety, Jury Told
• J&J Seeks OK Of $5M Baby-Product False Ad Settlement
• Deal Makers Buoyed After JPMorgan Forum Despite Clouds
• Agilent Rival Can't Trim Trade Secret Suit Over DNA Tech
• Actavis, Sandoz Rigged Anesthetic Cream Prices, Union Says
• Artificial Heart Maker Gets Ch. 11 Dismissal Approved
• Health Hires: 7 New Life Sciences, Health Additions
• Avoiding The Hidden Costs Of Bargain-Priced E-Discovery
• Taxation With Representation: Baker, Cleary, Paul, Kirkland
• Dabbing Into The Financial Side Of Marijuana
• Dance Marches On For Biosimilars In Amgen V. Sandoz
• Actavis, Sandoz Hit With Antitrust Suit Over Skin Drug
• High Court Takes Up Amgen-Sandoz Biosimilar Brawl
• KKR Inks $1.3B Deal For Hitachi Power Tool Unit
• FDA Floats New Oversight Plan On Lab Tests
• Health Care Enforcement Review And 2017 Outlook: Part 1
• DaVita, Fresenius Win Temporary Block Of HHS Rule Change
• Judge Won't Set 1st Calif. J&J Talc Cancer Trial Date Yet
• Atty Misconduct Not 'Egregious,' Judge Finds In Bayer Suit
• Zimmer Biomet To Pay $30M For Breaching FCPA Deal
• Sens. Reintroduce Bill Regulating Pay-For-Delay Deals
• Del. Theranos Suit Docs OK'd For Use In Other Actions
• Baxter To Pay $18M Over IV Fluid-Making Conditions
• Judge Knocks Out Imaging Patent For Inequitable Conduct
• Fed. Circ. Backs Eli Lilly Alimta Patent Win Under Akamai
• Agencies At Fault In Meningitis MDL Too, Surgery Center Says
• United Healthcare, Class Refute AGs' Protest To Hep C Deal
• Deals Rumor Mill: Johnson & Johnson, Onex, McDonald's
• A Record FCPA Year For Pharma
• Qiagen Asks Fed. Circ. To Lift DNA Sequencer Ban
• Trump's HHS Choice Inks Ethics Deal With Gov't Watchdog
• MIT Seeks $8M Fee Award In Gene Silencing Patent Fight
• Horizon Hits NJ Mail Order Pharmacy With $10M Suit
• The Outlook For The Pharmaceutical Industry Under Trump
• The Serious And Immense Impact Of A Medical Device Hack
• Saving Lawyers 1 Breath At A Time: Mindfulness In The Law
• FDA Sticks With Suffixes On Biosimilar Names
• Novo Nordisk Accused Of Fixing Prices To Hide Sales Slump
• Insurer Tells 9th Circ. Millennium Lab Suits Aren't Covered
• Shire Accused Of Cutting Pay-For-Delay Deal On ADHD Drug
• Greenberg Denies Fla. Biotech's $1B Malpractice Claims
• 7 Key Policies In HHS Inspector General's Exclusion Rule
• Theranos Seeks Out Of Blood-Testing Suits
• Meningitis-Linked Pharmacy Used Fake Names, Jury Told
• Feds Urge Against Rule Injunction In Dialysis Program Suit
• Alere Says Home Blood Test Class Action Is Full Of Holes
• ERISA Blocks Iowa Pharmacy Benefits Law, 8th Circ. Says
• Sanofi Accused Of Blocking Rival On Diabetes Drug
• Drug Return Co. Loses Bid To Trim $116M Diversion Case
• Latham & Watkins Steers Integra's $204M Derma Sciences Buy
• Surgeon Group Can't Nix LA's Spinal Implant Overcharge Row
• Consumer Orgs Ask 1st Circ. To Ax Momenta Antitrust Shield
• Czechia Says Several Courts Agree $328M Award Is Void
• Biotech Co. Hid Cancer Drug Concerns, Investors Say
• Children's Advil Ad Ban Is Proper, J&J Unit Tells 2nd. Circ.
• What To Expect From China's Anti-Monopoly Law This Year
• Understanding How Blockchain Could Impact Legal Industry
• Why The Learned Intermediary Doctrine Should Survive
• Harwood Lloyd Seeks $819K From Ex-Client In Generics Case
• Amgen Beats Decade-Old Investor Suit Over Off-Label Scheme
• Gilead Calls $50M Cancer Drug Bonus Demand 'Absurdity'
• FDA Reports Hacking Risk In St. Jude Medical Heart Devices
• Sanofi Can't Ditch Ex-Worker's FCA Claims Over Cancer Drug
• Deals Rumor Mill: Brookdale, Imagina Media, Carlyle Group
• 9th Circ. Won't Rehear Investor Suit Over Arena's Diet Drug
• Pharmacist Denied Problems Amid Meningitis Probe, Jury Told
• 1st Circ. Won't Rethink Nexium Pay-For-Delay Decision
• FDA OKs Abuse-Deterrent Opioid, Minus Some Label Claims
• Suits Over Defective Wright Hip Implant Stems Combined
• Whole Foods Hit With Class Action Over Supplement Claims
• Ex-NJ Pharma Execs Admit To Generic Drug Price-Fixing Plot
• McCain, Klobuchar Take 3rd Shot At Drug Import Bill
• Valeant Unloads $2B In Assets To Pay Down Debt
• Apparent Settlement Authority In A Paragraph IV Dispute
• Amgen Argues Decade-Old Derivative Suit Still Lacks Facts
• Mich. Spinal Surgeon Gets 20 Years For $2.8M Fraud Scheme
• 1st Circ. Won't Revive Spinal Therapy Co. Investor Suit
• The Firms That Dominated In 2016
• Drug Wholesalers To Pay $36M Over W.Va. Pill Mill Claims
• Supreme Court Rejects Merck Bid To Eye On-Sale Bar's Reach
• Omitted Testimony Affected Fee Fight, Firm Tells 11th Circ.
• Justices Won't Review PTAB's Power To Start AIA Reviews
• 5th Circ. Asked To Consolidate Hip MDL Bellwether Appeals
• Sanofi Vows Appeal After Drug Injunction Stay Is Denied
• Griffin Capital REIT Nabs NJ Office Building In $44M Deal
• Fed. Circ. Finds PTAB Wrongly Rejected Scalpel Patent Claim
• Meningitis Outbreak Was Murder, Feds Tell Jury
• Law360 Names Practice Groups Of The Year
• Ex-AdvoCare Director Must Arbitrate Claim Over CEO Job
• Takeda Inks $5.2B Deal For Oncology-Focused ARIAD
• Abbott, Alere Offer EU Antitrust Fixes For $5.8B Deal
• Popular Memory Booster Lacks Proof Of Benefits, FTC Says
• Fed. Circ. Finds No Standing For Appeal Of PTAB Drug Ruling
• SEC Judge Says PwC Auditor Must Face Fund Fraud Suit
• Atrium Medical Accused Of Hiding Surgical Mesh Risks
• $337M Has GSK Research Complex Trading Hands
• Top 5 Drug And Device Developments Of 2016
• Supreme Court Won't Hear ANDA Venue Case
• Investors Target Contraception Maker Over Stock Drop
• Merrimack Agrees To Sell Ipsen Cancer Drugs In $1.03B Deal
• FCPA Predictions For 2017
• Easing The Process For Requesting Experimental Drugs
• DOJ Subpoenas DaVita, Fresenius Over Dialysis Aid Program
• 3 Questions Shaping 2017 JPMorgan Health Care Conference
• Take Slashed Verdict Or Face New Med Mal Trial, Family Told
• Bankrupt Lensar Seeks Quick Access To Lender Cash
• Kyorin To Settle Apotex Pinkeye Meds Product-Hopping Suit
• Drug Wholesaler Cops To $100M Prescription Meds Fraud
• J&J Settles Latest Risperdal Case Before Trial
• The Biosimilars Litigation Landscape For 2017
• Giving Pfizer Rebate Info To Lawmakers Legal, Texas Says
• Illumina-Backed Cancer Screening Co. To Raise Over $1B
• Taxation With Representation: Bracewell, Gibson, Baker
• Mylan Sues IRS For Nixing $42M In Patent Litigation Write-Offs
• 5 FCA Issues To Watch As Trump Takes Power
• Real Estate Rumors: Pfizer, Heafey, Banco Bradesco
• Generic Drug Price-Fixing Suits Just Tip Of The Iceberg
• Pa. Judge Won't Ax $13.7M Pelvic Mesh Award
• KKR Injects $60M In Slayback Pharma
• The Duty To Supplement Expert Reports: Part 2
• 5 Insights From General Electric's Alex Dimitrief
• Amgen Wins Injunction On Sale Of Sanofi's Cholesterol Drug
• Alston & Bird DQ'd From CytImmune Noncompete Dispute
• NJ Appeals Judge And Mass Tort Jurist Carol Higbee Dies
• Staar Surgical Investors Snag Class Cert. In Stock-Drop Suit
• Lifewatch Must Turn Over Docs In Robocall Suit, FTC Says
• Genentech Presses For Cancer Drug Patent's Invalidation
• UK Competition Watchdog Taps 3 For Senior Roles
• Fenwick Guides Cancer Biotech Loxo's $120M Follow-On
• Ex-Insys Execs Plead Not Guilty To Pain Pill Kickback Con
• Mylan, Teva, Others Face Blood Pressure Drug Antitrust Suit
• Warner Chilcott Denied Sales Docs In Asacol Antitrust Suit
• J&J Denied Delay Request In Talc Cancer Missouri Trials
• Insomnia Device Maker Cerêve Raises $38M From KKR, Others
• The Path Forward For Industrial Hemp In Indian Country
• Houston Firm Wants High Court Review Of Fen-Phen Fee Row
• GE Urges Nix Of DQ 'Retaliation' In Incubator Patent Row
• The Duty To Supplement Expert Reports: Part 1
• Finding Conflict, Chief Justice Leaves Patent-Export Case
• Teva Ducks Whistleblower's Off-Label Marketing FCA Suit
• Judge Won't Toss Expert In Zimmer Trial, But Trims Claims
• Actavis, Mylan, Teva Rigged Cholesterol Drug Price, Suit Says
• South Korean Capital Markets Volume Hits 6-Year High
• Amneal Sees Key Suboxone Product-Hopping Claims Advance
• Wholesaler To Pay WV $3.5M Over Suspicious Drug Orders
• J&J Says Pfizer Unit Jointly Liable In Remicade Patent Suit
• PTAB Rejects MRI Patent Claims As Abstract Under Alice
• Investors Target Allergan After DOJ Price-Fixing Probe
• Families Hit Back At GSK'S Zofran Fraud Dismissal Bid
• Legal Loopholes For Dietary Supplements Must Be Sealed
• J&J Gets $1B Damages Cut In Half In Hip Verdict
• GSK Vaccine Sales Exempt From Antitrust Law, 9th Circ. Says
• Dental Instrument Patent Claims Found Invalid In PGR
• AbbVie Can't Trim Report In Testosterone Replacement MDL
• GOP Rep. Goodlatte Proposes Repeal Of Chevron Doctrine
• Texas Sues FDA Over Death Penalty Drug Import Delay
• Jury Verdict Upheld In Amgen Cholesterol Drug Patent Row
• Fed. Circ. Affirms PTAB Nix Of J&J Unit's Stent Patent
• 11th Circ. Nixes Procaps' Bid To Revive $255M Antitrust Suit
• Be Prepared For Law Firm Data Breach Litigation
• FDA Warning Wire: Enforcement Surge Targets Pharma Promos
• Trader Drops 3rd Circ. Appeal Of SEC Insider Trading Deal
• 'Unicorn' AppDynamics Leads 5 IPOs Filed In Year-End Blitz
• Medtronic Investors Get Shady-Study Suit Redo In 8th Circ.
• How A False Claims Act Case Works — Or Fails
• La. Bound To Flonase Settlement, GSK Tells 3rd Circ.
• Versant Ventures Nabs $400M For Biotech Investment Fund
• Boehringer, Sanofi Close Deal As FTC Orders Divestitures
• 1st Circ. Won't Revive FCA Suit Against Medtronic Unit
• Abbott To Wrap Up $25B St. Jude Buy With FTC's Approval
• Braeburn Pharmaceuticals Files For $150M IPO
• FTC Wants Endo's Challenge To Its Litigation Power Nixed
• 7 Legal Industry Predictions For 2017
• Life Sciences Cases To Watch In 2017
• Life Sciences Legislation And Regulation To Watch In 2017
• Product Liability Cases To Watch In 2017
• New Jersey Cases To Watch In 2017